247 related articles for article (PubMed ID: 25765793)
1. [Molecular mechanisms in the resistance of CML stem cells to tyrosine kinase inhibitors and novel targets for achieving a cure].
Tanaka H; Hirase C; Matsumura I
Rinsho Ketsueki; 2015 Feb; 56(2):139-49. PubMed ID: 25765793
[TBL] [Abstract][Full Text] [Related]
2. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
4. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
9. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
10. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
Irvine DA; Heaney NB; Holyoake TL
Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to therapy in CML.
Bhatia R
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):115-120. PubMed ID: 29222245
[TBL] [Abstract][Full Text] [Related]
12. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
Miyauchi M; Koya J; Arai S; Yamazaki S; Honda A; Kataoka K; Yoshimi A; Taoka K; Kumano K; Kurokawa M
Stem Cell Reports; 2018 Mar; 10(3):1115-1130. PubMed ID: 29429960
[TBL] [Abstract][Full Text] [Related]
13. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
Bansal A; Radich J
Curr Opin Hematol; 2016 Mar; 23(2):115-20. PubMed ID: 26825700
[TBL] [Abstract][Full Text] [Related]
14. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Erba HP
Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
17. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
18. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia.
Balabanov S; Braig M; Brümmendorf TH
Drug Discov Today Technol; 2014 Mar; 11():89-99. PubMed ID: 24847658
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
20. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
